The Aurora Funds
VC Fund
Durham, United States
The Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential.
- Total investments:
- 71
- Last investment:
- Lead investor:
- 25%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries The Aurora Funds invests in
Health CareBiotechnologySoftwarePharmaceuticalInformation Technology
Stages The Aurora Funds invests in
Series BSeries ASeries CFunding RoundSeries D
Countries The Aurora Funds invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jeff Clark
|
|||
Chris Kroeger
|
|||
Doug Gooding
|
|||
Richard Brown
|
|||
Investment Focus
Industry
- Health Care 15 (21%)
- Biotechnology 15 (21%)
- Software 13 (18%)
- Pharmaceutical 6 (8%)
- Information Technology 6 (8%)
Stage
- Series B 21 (30%)
- Series A 17 (24%)
- Series C 10 (14%)
- Funding Round 8 (11%)
- Series D 6 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jeff Clark
Managing Partner
|
Managing Partner | Total investments: 18 | Find email | |
|
Chris Kroeger
Partner
|
Partner | Total investments: 4 | Find email | |
|
Doug Gooding
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Richard Brown
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Scott Albert
Co-Founder & Venture Partner
|
Co-Founder & Venture Partner | Total investments: 4 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CardioFocus
|
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, andinvestigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias.CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. | Debt Financing / May 09, 2014 | |
Metabolon
|
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | $15M / Series E / Jan 06, 2014 | |
Argos Therapeutics
|
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $17.5M / Series E / Nov 20, 2013 | |
Regado Biosciences
|
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $51M / Series E / Dec 17, 2012 | |
Cardioxyl Pharmaceuticals
|
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate.Cardioxyl hasdeveloped industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age. | $28M / Series B / Nov 13, 2012 | |
|
Argos Therapeutics
|
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $25M / Series D / Apr 24, 2012 | |
|
Metabolon
|
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | Series D / Aug 29, 2011 | |
Digitalsmiths
|
Digitalsmiths drives video providers' ability to access video archives and offer personalized experiences through comprehensive, accurate, and actionable video metadata. The company's video discovery solutions are independent of content format or destination device, enabling personalized video experiences that are proven to drive moreengagement and greater monetization across mobile, broadband, tablet, and TV offerings. Digitalsmiths' customers include today's leading Hollywood studios, broadcasters, distributors, and publishers including Warner Bros., Turner, The CW Network, Paramount, Telepictures, and more.It was founded in 2006 and is based in Durham, North Carolina. | $12.5M / Series C / Apr 27, 2011 | |
|
CardioFocus
|
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, andinvestigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias.CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. | Series C / Feb 28, 2011 | |
|
Cardioxyl Pharmaceuticals
|
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate.Cardioxyl hasdeveloped industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age. | $15M / Aug 02, 2010 | |
| See all 71 investments → | |||
Co-Investors
Intersouth Partners
12 deals together
Cordova Ventures
5 deals together
Fletcher Spaght, Inc.
5 deals together
Harbert Growth Partners
5 deals together
Novak Biddle Venture Partners
5 deals together
Sevin Rosen Funds
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
Software VC Funds
31,919 investors
FAQ
What does The Aurora Funds invest in?
The Aurora Funds invests primarily in Health Care, Biotechnology and Software startups, most often at Series B and Series A stage. Most of the 71 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact The Aurora Funds?
Public channels for The Aurora Funds include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Aurora Funds?
The team at The Aurora Funds includes Jeff Clark (Managing Partner), Chris Kroeger (Partner) and Doug Gooding (Venture Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
